Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Fitch Affirms Banner Health System At 'AA-'; Upcoming Debt Considered
- Business Editors NEW YORK--BUSINESS WIRE--Aug. 22, 2002 Fitch Ratings affirms the outstanding underlying rating of 'AA-' on approximately $520 million in outstanding debt issued on behalf of Banner Health System BHS formerly known as Discovery Health System. The outstanding issues affected are listed below. Fitch affirms the rating...
- Research articles 2002-08-22
- Reclamation, Ranching, and Reservation: Environmental, Cultural, and Governmental Rivalries in Transitional Arizona
- In the spring of 1996, Tonto National Forest burned spectacularly. The Lone Fire swept over 61,000 acres, much of which was within the Four Peaks Wilderness Area. During the week of the fire, the issue of appropriate land use captured the media's attention, as well as the attention of government...
- Research articles 1998-09-22
- AZ's Seroquel Legal Bill Is $1.1B and Getting Bigger
- In AstraZeneca's Seroquel settlement with the U.S. Disrict Attorney in Pennsylvania, the headline number is $520 million. But the real cost to AZ is already much more than that: $1.1 billion. by Jim Edwards
- Blog posts 2009-10-30
- AZ Loses $13M Zoladex Appeal in "Do the Math!" Case
- AstraZeneca lost a federal appeals court ruling and must pay $13 million in damages for manipulating the price of prostate cancer drug Zoladex. The case involved an AZ campaign to persuade doctors to over-bill the government for Zoladex. It urged, "DO THE MATH!" in letters that explained how using Zoladex...
- Blog posts 2009-09-29
- E-Mail: AstraZeneca Knew in 1997 that Seroquel Caused Weight Gain
- AstraZeneca knew as far back as 1997 that Seroquel put patients at risk of weight gain, according to the company's own internal memos. The documents also appear to show that some AZ execs developed strategies to "neutralize" information that suggested Seroquel caused weight gain or diabetes, even after the FDA...
- Blog posts 2009-03-03
- AstraZeneca's Sex-for-Studies Seroquel Scandal: Did Research Chief Bias the Science?
- An AstraZeneca executive in charge of clinical research on Seroquel had sexual affairs with a researcher and a study writer, plaintiffs in a Florida lawsuit claim. BNET first wrote about the sex-for-secrets aspect of the Seroquel litigation on Feb. 17. Now Furious Seasons blogger Philip Dawdy revealed...
- Blog posts 2009-02-25
- Novartis, Boehringer Start Using Twitter Accounts
- AstraZeneca, Novartis, Vertex Pharmaceuticals and Boehringer Ingelheim have started experimenting with Twitter with varying degrees of enthusiasm, reports Pharmaceutical Executive. Drug companies have so far looked at social media with a mixture of fear and loathing. They believe perhaps wrongly that giving consumers more opportunities to talk...
- Blog posts 2009-02-18
- Seroquel Trial: Allegations of Sex-for-Secrets; AZ Wants Papers Sealed
- AstraZeneca is to argue in a Florida court next month that documents turned up in a lawsuit over weight-gain side effects of Seroquel should remain secret and sealed. The company is arguing it would be better for public health for Seroquel patients not to read the papers, according to The...
- Blog posts 2009-02-17
- AstraZeneca: 15,000 Layoffs Through 2013; Company the "Worst" in Its Class
- AstraZeneca announced plans for another 7,400 layoffs to take place before 2013. About 38 percent of those job cuts will come prior to 2010, the company said. The remainder will occur before 2013. The company expects the "restructuring" to cost $2.9 billion, but to save $2.5 billion...
- Blog posts 2009-01-29
- AstraZeneca's Role in Nobel Prizes Is Questioned
- UPDATE -- AstraZeneca failed to respond has now responded to BNET's request for comment, see below. The company also provided a statement to Pharmalot. The company confirmed its sponsorship of Nobel organizations but denied it had influenced the judges: "Because the Nobel Committee of Karolinska Institute, and not the Nobel companies,...
- Blog posts 2008-12-14
- Pharma Roundup: Infinity and AstraZeneca Split, Schering & Merck's PR Blunder, and More
- A fond farewell between Infinity and AstraZeneca, a dubious PR honor for S-P and Merck over Vytorin, Lilly's ImClone-related costs mount, generics cost less. by John Maas
- Blog posts 2008-12-11
- Abraxis Split Closes Door on a Rocky Patch for AstraZeneca
- The split between AstraZeneca and Abraxis over their copromotion of cancer drug Abraxane was expected among some Abraxis reps since August of this year. Now it's official. The end of the agreement comes as the patent on Casodex expires in April 2009 and the company this week saw mixed results...
- Blog posts 2008-11-26
- How AstraZeneca's U.S. Sales Reps Avoided the Current Round of Layoffs
- AstraZeneca staff in the U.S. dodged a bullet this morning as the company announced 1,400 layoffs -- but none of them in America. The job losses will come instead in the U.K., Spain, Belgium and Sweden. AZ's explanation of the move was a masterpiece in cynical management-speak and news-burying. Its...
- Blog posts 2008-11-20
- Pharma Roundup: Lawsuit for Roche, Teva Troubles for AstraZeneca, and More
- Roche must pay in lawsuit, Teva aiming for AstraZeneca's customers, AstraZeneca's new U.S. president, and Novartis in Cambridge. by John Maas
- Blog posts 2008-11-19
- Teva Sues AstraZeneca Over Crestor: $2.8 Billion on the Line
- Teva, the generic maker, is suing AstraZeneca, the holder of the original Crestor patent, claiming that AZ is somehow infringing on rights Teva acquired to the drug back in March 2007. The Crestor patent isn't supposed to expire until 2016 -- well beyond the industry's looming patent...
- Blog posts 2008-10-09
- The 10 Weirdest Drug Stories of the Month
- Another page has been torn off the calendar, and that means it's time to open up Big Pharma's vault of peculiarities and do a roundup of strange-but-true tales from the world of drugs that surfaced on my radar last month. I give you the 10 weirdest drug...
- Blog posts 2008-10-01
Additional Resources
- Exec Warned AZ on Negative Seroquel Results: "We Cannot Hide Them"; Info Later "Buried"
- AstraZeneca should promote publications manager John Tumas (if he's still with the company) and give him a bonus. In the ongoing Seroquel trials in Florida, he alone is emerging as the voice of reason inside that company. Back story: AstraZeneca is accused of marketing its antipsychotic without...
- Blog posts 2009-02-27
- AZ Seroquel Trial: Was It "Ghostwriting" or "Professional" Writing?
- The lawsuits filed against AstraZeneca over whether the company failed to warn Seroquel users of the weight gain and diabetes risks associated with the drug throws up an interesting sidelight on the practice of "ghostwriting." Back in 2005, according to the British Medical Journal and the Guardian,...
- Blog posts 2009-03-20
- Astrazeneca Plc (AZ). (Active Pharmaceutical Ingredient Watch).(reports on anticoagulant trials)(Brief Article)
- ASTRAZENECA PLC AZ reports that data from Phase III trials show oral anticoagulant Exanta ximelagatran reduced the risk of blood clots following orthopedic surgery by 63 percent compared to Lovenox. AZ posted a 5 percent slump ... ASTRAZENECA PLC AZ reports that data from...
- Research articles 2002-11-04
- KILL BW1194, AZ-RANES-INTERNATIONAL and KILL BW0205, CQN-AZ-RANES-INTERNATIONAL
- Please KILL BW1194, (AZ-RANES-INTERNATIONAL) WorldNet Casinos.com Delivers 22% Growth, which ran on Business Wire at 9:42 ET on 03/09/1999. Also KILL the CORRECTION, BW0205, (CQN-AZ-RANES-INTERNATIONAL) Replacing Sixth Graph in Ranes International Holdings Inc. Release Issued March 9, which ran on Business Wire at 11:52 ET on 03/10/1999. REPLACE...
- Research articles 1999-03-10
- << Previous
- page 1 of 1
- Next >>
Content Types
Premier Vendor Content Whitepapers, webcasts & resources from our Power Center Sponsors
